经尿道整块黏膜下水分离与常规电切治疗非肌层浸润性膀胱癌的随机多中心试验
HYBRIDBLUE 试验在 6 家德国学术中心随机分配 115 例 NMIBC 患者,比较 HAL 引导下 TUEB 与常规 TURBT。TUEB 组病理可评估肌层浸润的比例为 86%(48/56),显著高于 TURBT 组的 63%(37/59,P=0.006);R0 率分别为 57%(30/56)与 9%(5/59,P<0.001)。两组均无≥III 级并发症。
要点
- TUEB 组病理可评估肌层浸润的比例为 86%,显著优于 TURBT 组的 63%(P=0.006)。
- TUEB 组 R0 率为 57%,显著高于 TURBT 组的 9%(P<0.001)。
- 两组均未观察到≥III 级并发症,围手术期安全性良好。
核心结论
- TUEB 在围手术期终点上临床安全,且病理对肌层浸润的可评估性显著优于常规 TURBT。
- 该发现提示 TUEB 有潜力降低早期二次电切率,但仍需以无复发生存为主要终点的大型研究评估肿瘤学疗效。
研究设计与样本
- 随机、多中心、优效性设计试验(HYBRIDBLUE),2012 年 9 月至 2015 年 8 月在 6 家德国学术中心开展。
- 预筛查 305 例后,最终 115 例纳入分析(TUEB 56 例,TURBT 59 例)。
- 样本量基于文献假设 TURBT 与 TUEB 可准确评估肌层浸润的比例分别为 50% 与 80%。
- 分组为 Group I:HAL 引导下 TUEB;Group II:常规 HAL 引导下 TURBT。
- 主要终点为可可靠病理评估肌层浸润的标本比例。
主要发现
- 可充分病理评估(含肌层内容与切缘 R0 vs R1)在 TUEB 组为 48/56(86%),TURBT 组为 37/59(63%),P=0.006。
- R0 在 TUEB 组为 30/56(57%),TURBT 组为 5/59(9%),P<0.001。
- 两组均未观察到≥III 级并发症。
- 3 个月复发:TUEB 组 3 例 vs TURBT 组 7 例(P=0.33)。
- 12 个月复发:TUEB 组 19 例 vs TURBT 组 11 例(P=0.08)。
关键数值与推荐
- 主要终点达标:TUEB 组可充分病理评估比例 86%(48/56)vs TURBT 组 63%(37/59),P=0.006。
- R0 率:TUEB 组 57%(30/56)vs TURBT 组 9%(5/59),P<0.001。
- 3 个月复发率比较 P=0.33,12 个月复发率比较 P=0.08。
- 两组均无≥III 级并发症报告。
临床怎么用
- TUEB 可提高 NMIBC 标本病理可评估肌层浸润的比例,有助于更准确分期。
- TUEB 显著提高 R0 率,可能减少早期二次电切的需要。
- 围手术期安全性方面,TUEB 未增加≥III 级并发症。
- 复发相关终点在本研究中未显示显著差异,暂不能据此改变复发监测策略。
局限性
- 样本量较小(共 115 例),主要终点为病理可评估性而非无复发生存。
- 随访至 12 个月的复发分析为次要终点,P 值未达显著(P=0.33 与 P=0.08)。
- 作者指出仍需以无复发生存为主要终点的大型研究评估两种技术的肿瘤学疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether transurethral en bloc submucosal hydrodissection of bladder tumours (TUEB) improves the quality of the resection compared to conventional transurethral resection of bladder tumour (TURBT) in patients with non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: A randomised, multicentre trial (HYBRIDBLUE) was conducted with a superiority design. Six German academic centres participated between September 2012 and August 2015. Based on literature analysis, a sample size for accurate histopathological assessment concerning muscle invasion was assumed to be feasible in 50% (P0 = 0.5) of TURBT and 80% of TUEB cases. After pre-screening of a total of 305 patients, participants were allocated to two study arms: Group I: hexaminolevulinate (HAL)-guided TUEB; Group II: conventional HAL-guided TURBT. The primary endpoint was the proportion of specimens that could be reliably evaluated pathologically concerning muscle invasiveness. Secondary endpoints included rates of histopathological completeness of the resection, muscularis propria content, recurrence, and complication rates. RESULTS: A total of 115 patients (TUEB 56; TURBT 59) were eligible for final analysis. Adequate histopathological assessment, which included muscularis propria content and tumour margins (R0 vs R1), was present in 48/56 (86%) TUEB patients compared to 37/59 (63%; P = 0.006) in the TURBT group. R0 was confirmed in 30/56 TUEB patients (57%) and five of 59 TURBT patients (9%; P < 0.001). No complications of Grade ≥III were observed in both arms. At 3 and 12 months, three and 19 patients recurred in the TUEB group vs seven and 11 patients in the TURBT group, respectively (P = 0.33 and P = 0.08). CONCLUSIONS: In this randomised study, TUEB was shown to be clinically safe regarding perioperative endpoints. An adequate histopathological assessment concerning muscle invasion was significantly better assessable in the TUEB arm compared to standard TURBT. This finding indicates the clinical potential for reducing the rate of early re-resections. Yet, a larger study with recurrence-free survival as the primary endpoint is needed to assess the oncological efficacy between both techniques.
引用
- Gakis G, Karl A, Bertz S, et al. Transurethral en bloc submucosal hydrodissection vs conventional resection for resection of non-muscle-invasive bladder cancer (HYBRIDBLUE): a randomised, multicentre trial. BJU Int. 2020. PMID: 32578332. doi:10.1111/bju.15150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。